Abstract
The study investigated Eudragit coated microemulsion (ME) for oral delivery of spiramycin in treatment of toxoplasmic encephalitis. The goal was to augment the efficacy of ME by protection from gastrointestinal conditions and/or providing bioadhesion. Uncoated and coated MEs comprise labrafil as oil, cremophore EL as surfactant and labrasol as cosurfactant were prepared. The MEs were characterized with respect to shape, droplet size and in vitro drug release. Optimum formulations were assessed against cerebral toxoplasmosis. This involved oral administration of spiramycin solution, uncoated and coated MEs to Me49 Toxoplasma gondii infected mice at early and late stages. The uncoated ME droplets were spherical with average size of 147 nm. The coated ME droplets were polygonal with average size of 142 nm. Spiramycin release rate was significantly higher from uncoated ME. The parasitic load and histopathology reflected superiority of spiramycin coated ME over uncoated ME and both were more effective than spiramycin solution. The same trend was evident in early and late stages of infection. Interestingly, all formulations showed better efficiency in late stage of infection. The study introduced eudragit coating of ME as a tool to augment oral delivery from microemulsions. The developed system hastened the efficacy of spiramycin against toxoplasmic encephalitis.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
